All analyses
AI analysis

Ceylon Hospitals Plc: research report

Moderately undervaluedbullishOct 20, 2026

Evidence points to a stronger hospital group than the moderately undervalued price suggests, with quarterly revenue and profit both growing. The catch is operating profit fell 6.6% as margin narrowed.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bullish

  • June-quarter revenue grew 8.5% and net profit grew 4.7%, extending the group’s recovery in earnings.
  • Annual debt fell to LKR 1.3 billion while interest cover improved to 8.1 times, reducing the burden of financing the business.
  • The latest audited year delivered 44.9% net-profit growth, supported by a higher operating profit base.

Against this. June-quarter operating profit fell 6.6% and operating margin narrowed to 14.3%, showing that the latest profit growth did not come from stronger core operations.

Operating margin
14.9%
from 13.5% a year earlier
Net margin
10.6%sector 13.0%
from 9.4% a year earlier, revenue +26.8%
Return on equity
8.7%
twelve months to Sep 30, 2026, unaudited
P/E
11.4sector 11.8
earnings Rs 5.68 per share, year to Mar 2026
P/B
0.88sector 1.36
book Rs 73.57 per share
Dividend yield
1.69%sector 0.00%
19.4% of earnings paid out

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Oct 20, 2026. Sector figures are the median of 6 listed companies in the same sector.

Overview

Ceylon Hospitals operates the Durdans hospital, diagnostics and laboratory network, and related medical education businesses. The central change is that revenue and net profit continued to rise in the latest quarter, but the hospital group converted less of its revenue into operating profit than a year earlier.

Price performance

At LKR 57.00 on 20 October 2026, CHL had fallen 8.1% over three months against a 5.8% ASPI decline, while its 20.6% one-year return remained well ahead of the index’s 9.9% fall. The share sits 22.1% of the way up its adjusted 52-week range, after a 1:4 split on 5 March 2026 mechanically changed the screen price and share count but not the size of the company.

Recent volatility and volume are below this share’s own yearly norms. The three-year record contains two falls of 15% or more, with the deepest 40% and not yet recovered. Liquidity is limited: a LKR 1 million order is more than everything that trades on a typical day, 405% of it, so a position of that size is a large part of normal trading activity.

Valuation

The market-wide assessment starts in the moderately undervalued band, scoring 74 of 100 on price against filed book value, earnings and dividends. At 10.0 rupees paid for every rupee of trailing profit, the P/E is close to the healthcare median of 10.58 times; the 0.8 times P/B means the shares trade below the LKR 71.56 per-share book value and below the sector median of 1.54 times. The 8.1% trailing return on equity is the link between those earnings and book value.

Against its own record, P/B is “more expensive than 80% of days since January 2019” and P/E is “more expensive than 65% of days since January 2019”. That contrast with sector-relative discounts means the present price is cheaper than comparable healthcare shares on book value, but not cheap against CHL’s own trading record. A buyer at this price is relying on a latest quarter that supplied 29.7% of trailing EPS; at the prior-year quarter’s margin, the P/E would be 9.9 times rather than 10.0 times.

The 1.9% dividend yield is below the sector median of 2.7%. The payout has risen from LKR 0.5 per share in FY2024 to LKR 1.0 in FY2025 and LKR 1.1 in FY2026, while dividend cover was 5.16 times, leaving most earnings within the business.

News and sentiment

Direct company coverage is thin, with one material article in the past 90 days and neutral reported tone. An article dated 19 October reported that Durdans exited Digital Health, the Doc990 operator; no terms attributable to Ceylon Hospitals were disclosed, so its earnings effect cannot be sized.

The LKR 1.10 interim dividend went ex-dividend on 1 June 2026 and was paid on 18 June. A buyer today does not receive that dividend. The 1:4 subdivision took effect on 5 March 2026 and changed every per-share figure mechanically, without changing the group’s underlying assets or earnings.

Financials

June-quarter revenue rose 8.5% to LKR 3.0 billion, but operating profit fell 6.6% to LKR 427 million. Net profit nonetheless rose 4.7% to LKR 323 million, meaning the profit increase was smaller than sales growth and core operating performance softened.

Gross margin narrowed from 59.2% to 56.9%, operating margin from 16.6% to 14.3%, and net margin from 11.2% to 10.8%. The June gross margin was among the weakest of seven comparable June quarters, while operating and net margins ranked in the middle of that record. LKR 104 million was absorbed below operating profit by finance costs, tax and other items, which limited the amount of operating earnings reaching net profit.

Total equity rose from LKR 12.1 billion a year earlier to LKR 12.9 billion. Shares in issue are 167.6 million, compared with about 42.0 million before the March split; the fourfold increase is mechanical, so historic EPS and book value per share cannot be read as an underlying deterioration. The twelve months to June 2026 generated LKR 11.2 billion of revenue and an 8.1% return on equity. Minority shareholders received 9.6% of the latest audited year’s profit, so group net profit is not entirely attributable to the ordinary shares being valued.

Risks

The leading business risk is margin pressure: the latest quarter produced more revenue but less operating profit, and gross margin ranked near the bottom of its comparable June record. Healthcare-sector context also points to household pressure, with essentials including healthcare accounting for 58% of spending in the cited survey; this is an industry backdrop rather than evidence of a measured effect on CHL.

Balance-sheet risk is moderate rather than acute. Debt was LKR 1.3 billion at the latest audited year-end, equal to 11.2% of owners’ equity, and operating profit covered the interest bill 8.1 times. The current ratio was 1.47 times, meaning it had LKR 1.47 of short-term assets, including receivables and supplies, for each LKR 1 of bills due within a year. Operating cash flow was 1.07 times operating profit, so audited operating earnings were converted into cash, while free cash flow was LKR 920 million.

The voting line is also illiquid, and the share’s record includes a still-unrecovered 40% drawdown. This makes trading access and exit capacity a practical risk independent of the group’s operating results.

Outlook

As at 20 October 2026, the next specific catalyst is the September 2026 interim filing, expected between 6 and 14 November. It will show whether June’s lower operating margin was a one-quarter setback or whether revenue growth is continuing to outpace profit growth.

The available data cannot quantify the effect of the reported Doc990 exit. The healthcare backdrop combines higher public health allocations with household-budget pressure, but neither development establishes a direct impact on Ceylon Hospitals’ revenue or earnings.

About this report. Generated on Oct 20, 2026 from market data up to Oct 20, 2026, 1 material news articles over 90 days and financials to Jun 30, 2026, and scored 74 of 100 on value (moderately undervalued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports